BioPharma APAC Perspective:

Bora's acquisition of Upsher-Smith for $210 million marks a pivotal moment for the pharmaceutical giant. This strategic move not only catapults Bora into a prominent position in the US market but also positions it as a formidable global player. The deal not only expands Bora's capacity for CDMO services but also enriches its portfolio with Upsher-Smith's respected name, diverse product range, and established industry relationships. This acquisition is poised to significantly elevate Bora's standing, opening doors for enhanced growth, market competitiveness, and accelerated development in the pharmaceutical industry.

In a strategic move, Bora Pharmaceuticals is set to acquire Upsher-Smith, a pharmaceutical manufacturer with a rich history dating back to 1919. The $210 million deal, subject to regulatory approvals, positions Bora for substantial growth in the US market. Upsher-Smith's diverse portfolio of 48 generic products, along with its well-established manufacturing facilities in Minnesota, brings solid capabilities and a respected name to Bora's expanding global presence.

The acquisition not only enhances Bora's capacity for Contract Development and Manufacturing Organization (CDMO) services but also strengthens its foothold throughout the entire US market. Upsher-Smith's extensive experience in the generics sector, coupled with a robust distribution network, offers immediate revenue opportunities and valuable industry expertise. Bobby Sheng, Chairman and CEO of Bora Group, sees this as a significant milestone, marking Bora's critical expansion in the US and positioning it as a global competitor in both CDMO and commercial Rx business.

With Upsher-Smith's USFDA-approved manufacturing facilities providing a local stronghold for Bora, the deal is poised to accelerate growth. The transaction underscores Bora's commitment to successful integration, driving expansion, and solidifying its standing in the pharmaceutical industry.